Connection
Pavel Jedlicka to Jumonji Domain-Containing Histone Demethylases
This is a "connection" page, showing publications Pavel Jedlicka has written about Jumonji Domain-Containing Histone Demethylases.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.839 |
|
|
|
-
Sobral LM, Hicks HM, Parrish JK, McCann TS, Hsieh J, Goodspeed A, Costello JC, Black JC, Jedlicka P. KDM3A/Ets1 epigenetic axis contributes to PAX3/FOXO1-driven and independent disease-promoting gene expression in fusion-positive Rhabdomyosarcoma. Mol Oncol. 2020 10; 14(10):2471-2486.
Score: 0.684
-
McCann TS, Sobral LM, Self C, Hsieh J, Sechler M, Jedlicka P. Biology and targeting of the Jumonji-domain histone demethylase family in childhood neoplasia: a preclinical overview. Expert Opin Ther Targets. 2019 04; 23(4):267-280.
Score: 0.619
-
Jedlicka P. The potential of KDM3A as a therapeutic target in Ewing Sarcoma and other cancers. Expert Opin Ther Targets. 2017 11; 21(11):997-999.
Score: 0.563
-
Sechler M, Parrish JK, Birks DK, Jedlicka P. The histone demethylase KDM3A, and its downstream target MCAM, promote Ewing Sarcoma cell migration and metastasis. Oncogene. 2017 07 20; 36(29):4150-4160.
Score: 0.541
-
Parrish JK, Sechler M, Winn RA, Jedlicka P. The histone demethylase KDM3A is a microRNA-22-regulated tumor promoter in Ewing Sarcoma. Oncogene. 2015 Jan 08; 34(2):257-62.
Score: 0.432